STRASBOURG, FRANCE, January 9th, 2025 -- CORE Biogenesis, a pioneering biotechnology company, has confirmed compelling new results highlighting the superior delivery capabilities of its Oleosome-Protein fusions. This innovative technology transcends the stratum corneum barrier, ensuring penetration into the epidermis and dermis a breakthrough for protein and peptide-based actives in Personal Care and Cosmetics, where challenges like instability and poor penetration have long constrained efficacy.
Leveraging its proprietary plant biofactory platform, CORE Biogenesis produces biomimetic proteins and peptides within Camelina sativa plants housed in its closed greenhouse facilities in Strasbourg. These actives are fused with Oleosomes, naturally occurring spherical carriers composed of phospholipids, oil, and vitamin E. The Oleosome-Protein fusion not only stabilizes protein and peptide structures by 8-10 times but also enables deep delivery, a critical advancement validated through skin explant studies.
“Traditionally, large peptides and proteins have struggled to penetrate the skin due to their size and instability,” comments Alexandre Reeber, President and CEO of CORE Biogenesis. “Our studies conclusively show that Oleosome Protein fusions deliver actives to the dermis, whereas Protein alone stops in the epidermis —a transformational result for the industry.”
CORE Biogenesis has launched two groundbreaking active ingredients into personal care: peauvita™ and peauforia™, next-generation growth factors clinically proven to address the four primary signs of aging within 14 days in a placebo-controlled study. Building on this success, the company is planning to expand its portfolio to include other proteins and peptides that can benefit from its cutting-edge plant biofactory technology.
“Beyond growth factors, we’ve successfully produced many proteins and peptides using our platform, addressing stability and delivery challenges that have limited innovation in the market,” said Tony Abboud, Chief Commercial Officer (CCO) at CORE Biogenesis. “This capability opens the door to co-developing next-generation actives with ingredient suppliers and brands for the Personal Care, Health, and Wellness sectors.”
To support its growth, CORE Biogenesis is building a direct sales team in Europe and Asia and plans to showcase its innovations at major industry events throughout 2025, beginning with Cosmet’Agora in France next week, and Makeup in LA next month.
To present its data, the company is also hosting a global webinar in collaboration with Covalo, titled “Deeper Clinical Results: Novel Delivery Systems for Protein and Peptide-based Actives” featuring industry experts Ameann DeJohn and Alison Cutlan on January 28, 2025.
👉 Space is limited, reserve your spot here: https://share.hsforms.com/11GcY7cS7QSGTPPFKM_5qrg34jvj
CORE Biogenesis uses its proprietary bioproduction technology to manufacture recombinant proteins for the biopharma and cosmetic industries. Founded in 2020 by Dr. Chouaib Meziadi, CSO, and Alexandre Reeber, CEO, the company is committed to sustainable innovation and redefining the possibilities of protein-based actives.
For more information please contact:
Investor contact - alexandre.reeber@corebiogenesis.com
Customer contact - tony.abboud@corebiogenesis.com